Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co (SHSE:688505) Research & Development: ¥180.0 Mil (TTM As of Dec. 2025)


SHSE:688505 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd SHSE:688505
67 GF Score
Price ¥7.72
GF Value ¥6.49
Valuation Modestly Overvalued
! 2 Warning Signs
View Full Analysis

What is Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Research & Development?

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co SHSE:688505 -1.28% 67 Research & Development is ¥180.0 Mil as of Dec. 2025. GuruFocus rates SHSE:688505 with a GF Score™ of 67/100 and a GF Value™ of ¥6.49 (Modestly Overvalued). The stock has 2 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Research & Development for the three months ended in Dec. 2025 was ¥113.9 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was ¥180.0 Mil.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co  (SHSE:688505) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Research & Development Related Terms

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Research & Development Historical Data

* Premium members only.

The historical data trend for Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Research & Development Chart

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 224.39 226.85 243.76 314.16 357.94

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Quarterly Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Jun25 Sep25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 81.15 78.42 0.00 66.06 113.91
SHSE:688505
67GF Score
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd SHSE:688505
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥180.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of ¥180.0 Mil mean?
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co (SHSE:688505) has a Research & Development of ¥180.0 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co and its competitors.
Is Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Research & Development too high?
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's current Research & Development is ¥180.0 Mil. Overall, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co has a GF Score™ of 67/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Research & Development compare to ZTS and UTHR?
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Research & Development of ¥180.0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co and its competitors. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's current Research & Development is ¥180.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co (SHSE:688505) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥6.49, compared to a current price of ¥7.72 — trading 19% above its estimated fair value. The current Research & Development is ¥180.0 Mil. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's overall GF Score™ is 67/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co (SHSE:688505), the current Research & Development is ¥180.0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co (SHSE:688505) Overvalued in 2026?

Based on GuruFocus' analysis, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co stock appears to be overvalued. The current stock price of ¥7.72 is trading 19% above its estimated GF Value™ of ¥6.49. GuruFocus considers Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co to be Modestly Overvalued.

Key valuation signals for SHSE:688505:

  • Research & Development: ¥180.0 Mil
  • GF Value™: ¥6.49 vs. price of ¥7.72 (19% above fair value)
  • GF Score™: 67/100 with 2 warning signs

No single metric tells the full story. See the SHSE:688505 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Business Description

Other Exchanges 01349:Hong Kong
Address 308 Cailun Road, Zhangjiang Hi-Tech Park, Pudong, Shanghai, CHN, 201210
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd is engaged in the research, development, manufacturing, and sale of biopharmaceutical products. Its product portfolio includes ALA (Aminolevulinic acid Hydrochloride); FuMeiDa and Libord. The company has launched it's four types of photodynamic drugs in China market, namely hematoporphyrin, aminolevulinic acid hydrochloride, Verteporfin and Hemoporfin. Geographically, it derives revenue from Mainland China.
67GF Score

Get the complete analysis for SHSE:688505

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥7.72
Price
¥6.49
GF Value